Stephen W. Kidder’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stephen W. Kidder’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,525	Closed	-$282K	–	91
2016 Q4	$282K	Hold	7,525	–	–	0.11%	87
2016 Q3	$511K	Hold	7,525	–	–	0.2%	64
2016 Q2	$418K	Hold	7,525	–	–	0.17%	75
2016 Q1	$473K	Sell	7,525 -150	-2%	-$9.97K	0.19%	71
2015 Q4	$723K	Buy	7,675 +700	+10%	+$64.9K	0.31%	61
2015 Q3	$560K	Sell	6,975 -1,100	-14%	-$122K	0.28%	58
2015 Q2	$968K	Sell	8,075 -1,000	-11%	-$120K	0.44%	52
2015 Q1	$948K	Hold	9,075	–	–	0.41%	53
2014 Q4	$880K	Hold	9,075	–	–	0.38%	56
2014 Q3	$709K	Hold	9,075	–	–	0.32%	59
2014 Q2	$574K	Hold	9,075	–	–	0.38%	47
2014 Q1	$609K	Sell	9,075 -9,075	-50%	-$703K	0.41%	48
2013 Q4	$1.17M	Sell	18,150 -2,000	-10%	-$119K	0.8%	42
2013 Q3	$1.29M	Hold	20,150	–	–	1%	37
2013 Q2	$625K	Buy	+20,150	New	+$536K	0.5%	46

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Stephen W. Kidder's ALNY Position: Q1 2017 in Review

Stephen W. Kidder sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 7,525 shares — an estimated $282K sold.

Stephen W. Kidder first reported a position in ALNY in Q2 2013 and held it in 15 quarters. The position peaked at $1.29M in Q3 2013. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Stephen W. Kidder reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Stephen W. Kidder sold 7,525 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $282K.
Stephen W. Kidder first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Stephen W. Kidder's Alnylam Pharmaceuticals position peaked at $1.29M in Q3 2013.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Stephen W. Kidder's 13F filing for Q1 2017, filed 15 May 2017.